Pharma-AI Collaboration Drives ~$3M Cost Reduction by Using Highly Curated Public Data

Key Highlights
  • A leading genomics-based drug discovery company wanted to accelerate the identification of putative targets across immunological diseases and cancer by complementing their research with publicly available data.
  • The highly curated data on Elucidata’s Public OmixAtlas played a pivotal role in helping pharma company identify 1 target for an immunology group in just 6 months, as compared to the usual time period of 2-3 years.
  • The partnership helped de-risk advancement to phase II leading to lower trial costs there by saving ~ $3M. It also worked in favor of saving time of R&D and bioinformatics personnel by freeing up ~2000 hours annually.

All Case Studies